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Background: The oncogenic roles contributed by the Akt/PKB kinase family remain controversial and presumably
depend on cell context, but are perceived to be modulated by an interplay and net balance between various
isoforms. This study is intended to decipher whether distinct Akt kinase isoforms exert either redundant or unique
functions in regulating neoplastic features of breast cancer cells, including epithelial-mesenchymal transition (EMT),
cell motility, and stem/progenitor cell expansion.
Results: We demonstrate that overactivation of Akt signaling in nonmalignant MCF10A cells and in primary
cultures of normal human mammary epithelial tissue results in previously unreported inhibitory effects on EMT, cell
motility and stem/progenitor cell expansion. Importantly, this effect is largely redundant and independent of Akt
isoform types. However, using a series of isogenic cell lines derived from MCF-10A cells but exhibiting varying
stages of progressive tumorigenesis, we observe that this inhibition of neoplastic behavior can be reversed in
epithelial cells that have advanced to a highly malignant state. In contrast to the tumor suppressive properties of
Akt, activated Akt signaling in MCF10A cells can rescue cell viability upon treatment with cytotoxic agents. This
feature is regarded as tumor-promoting.
Conclusion: We demonstrate that Akt signaling conveys novel dichotomy effects in which its oncogenic properties
contributes mainly to sustaining cell viability, as opposed to the tumor suppressing effects, which are mediated by
repressing EMT, cell motility, and stem/progenitor cell expansion. While the former exerts a tumor-enhancing effect,
the latter merely acts as a safeguard by restraining epithelial cells at the primary sites until metastatic spread can be
moved forward, a process that is presumably dictated by the permissive tumor microenvironment or additional
oncogenic insults.
Keywords: Activated Akt signaling, Breast epithelia, Epithelial-mesenchymal transition, Motility, Stem-progenitor
cellsBackground
The serine/threonine kinase Akt/PKB has emerged as one
of the most pivotal protein kinase family that plays critical
roles in regulating pleiotropic cellular and physiological
processes [1]. In response to ligand stimulation from cyto-
kines or from growth factors such as the insulin-like growth
factor-I (IGF-I) and the epidermal growth factor (EGF)
family, receptor tyrosine kinases are phosphorylated, an
event which subsequently activates phosphatidylinositol 3-
kinase (PI3K) signaling and stimulates the Akt axis as well* Correspondence: hlin@udel.edu
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reproduction in any medium, provided the oras other downstream signaling pathways [1]. To commence
this signaling cascade, the lipid second messenger phospha-
tidylinositol (3,4,5)-triphosphate (PIP3) is first synthesized
from PIP2 by PI3K and then recruits both Akt and
phophoinositide-dependent kinase 1 (PDK1) to the plasma
membrane through the pleckstrin homology (PH) domain
where the highly conserved Thr308 is phosphorylated by
PDK1 [2,3]. Phosphorylation of this residue as well as
Ser473, catalyzed by the mammalian target of rapamycin
complex 2 (mTORC2), together confers full activation of
Akt [4], thereby activating various downstream factors by
phosphorylating arrays of targets [1]. Conversely, this acti-
vation cascade can be blocked by cellular inhibitors includ-
ing the phosphatase and tensin homolog (PTEN) and
INPP4B which directly antagonize PI3K function via
dephosphorylating PIP3, thereby abrogating PIP3-mediatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and Akt [5,6]. As a result, target cells can be returned to a
basal level in a standby mode. However, in vitro engineered
Akt kinase can override this regulatory mechanism and
maintain it in a “supercharged” stage. This can be done by
insertion of myristoylated (Myr) tag at its N-terminus
which results in anchoring Akt in plasma membrane an-
chorage as well as constitutive activating Akt independently
of PI3K activity [7,8].
Three main Akt isoforms, Akt1/PKBα, Akt2/PKBβ, and
Akt3/PKBγ, have been discovered in mammals and they
share two highly conserved regions in the PH and kinase
catalytic domain [1]. Studies employing gene ablation in la-
boratory animals have revealed non-redundant functions of
Akt isoforms. Akt1 null mice are small with significant
growth defects [9,10], whereas mice depleted of Akt2 de-
velop insulin-resistant diabetes [11]. Conversely, Akt3 abla-
tion leads to reduced brain size in mice [12,13]. Notably,
differences in physiology and microenvironment might
exist between mice and humans. Clinical studies demon-
strated that specific isoforms can be amplified in different
types of human cancer, furthering a notion that Akt kinase
dictates transformation phenotypes of various carcinomas
in an isoform-specific manner, rather than in a redundant
fashion [14]. Yet, how etiological cause(s) determine which
of the 3 isoforms shall be activated and subsequently trans-
mit unique downstream targets to exert distinct outcomes
remains largely unknown.
Furthermore, components within the PI3K pathway are
frequently dysregulated in human cancers [15]. For in-
stance, activating mutations of PIK3C (the catalytic subunit
of PI3K) often occur in prevalent carcinomas [16]. More-
over, PTEN has been proven to be one of the most com-
monly altered genes in human malignancies [17]. In
contrast, gain-of-function Akt mutations are relatively un-
common [15,17] and most frequently occur at residue 17
(namely E17K) which resides in the PH domain and is thus
unlikely to directly sustain kinase activation. Based on clin-
ical studies, it is becoming doubtful that Akt activation per
se is indeed important for driving various neoplastic pheno-
types. In support of this notion, activated Akt signaling was
previously shown to induce senescence as well as inhibit
breast cancer cell motility and invasion [18-21].
Among its known neoplastic features, Akt kinase is
involved in EMT, which is characterized by the loss of
epithelial characteristics and the acquisition of a mesen-
chymal phenotype [22]. In carcinomas, EMT is associated
with increased aggressiveness, tumor invasion, and meta-
static potential, and endows mammary stem cell properties
[23-25]. A recent study demonstrated that Akt activation
via down-regulated PTEN can enrich normal as well as
malignant human mammary stem/progenitor cells and
these aberrations can be rescued by Akt inhibitors [26].
Nevertheless, a mounting body of evidence supports theidea that Akt signaling regulates cell migration and EMT
via an isoform-specific and context-dependent manner
[27-30]. It remains largely unclear whether Akt kinase
would result in different outcomes, in respect to normal
versus malignant breast epithelia. Moreover, it remains puz-
zling as to whether Akt activation augments a whole array
of transformation phenotypes collectively leading to onco-
genesis, or if it exerts paradoxical effects on both promoting
and impeding neoplastic phenotypes.
To investigate these issues, we have expressed all three
isoforms of constitutively active Myr-Akt kinase in human
mammary epithelia ranging from nonmalignant primary
epithelia, an immortalized cell line, and a series of cell lines
exhibiting varying degrees of malignant behavior. This wide
array of target cells has allowed us to reveal how Akt influ-
ences oncogenic phenotypic changes corresponding to the
cell context in varying degrees of malignancy. We have dis-
covered that Akt, in an isoform-independent fashion, has
tumor suppressive properties since it can inhibit of EMT,
decrease cell motility, and reduce the stem/progenitor cell
population. These aberrations are rather prominent in non-
malignant epithelia but diminish as cells progress to a more
neoplastic state. However, even in non-malignant cells, Akt
activation can have tumor-promoting properties since it
can promote cell survival following exposure to chemother-
apeutic agents. Taken together, this study denotes a novel
paradigm that activated Akt signaling can have both
tumor-suppressing and tumor-promoting properties.
Results
Activated Akt signaling impedes EMT and attenuates cell
migration in non-malignant breast epithelia
Our preceding report revealed that, in non-malignant
breast epithelial cell line such as MCF10A, Akt signaling
can be activated by tumor microenvironmental stimuli pro-
voked from an exposure to breast cancer-associated fibro-
blasts [31]. However, it remains rather controversial how
Akt signaling affects breast oncogenesis since data gener-
ated from animal models is inconsistent with data from
clinical studies [28,30,32], despite the fact that various iso-
forms may display distinct and opposing effects [27-30].
Herein, we assessed the effects of activated Akt signaling
on neoplastic behavior in human breast epithelia.
As breast cancer mortality is largely ascribed to meta-
static spread that is tightly related to EMT and cell motility,
the influence of Akt activation on these aberrations is of
great interest. Hence, constitutive expression of Akt was
engineered by transducing Myr-Akt via retroviral-delivery
system into MCF10A cells. Two weeks later when maximal
expression and Akt kinase activity was reached (data not
shown), total RNA was extracted from the resultant cells
and subjected to RT-qPCR assays to quantify the expres-
sion levels of a panel of known EMT transcripts, including
the epithelium-associated protein E-cadherin (E-cad) as
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(FN1), FOXC2, N-cadherin (N-cad), Twist, and Vimentin
(VIM) [22,33]. Interestingly enough, regardless of isoform
types, activated Akt signaling consistently yielded a notice-
able induction of E-cad along with an inhibition of various
mesenchymal-associated transcripts (Figure 1A; and the left
panel of Figure 2). Western blotting confirmed that the
changes in mRNA levels are also seen at the protein level
(Figure 1B). This observed suppression of EMT is mirrored
by a moderate decrease in cell motility, as measured by
using transwell migration and wound-healing scratch assays
(left panels of Figure 3A, 3B; and 3C). In these experiments,
activation of either Akt1 or Akt3 resulted in a greater than
2-fold inhibition of motility compared to vehicle controls,
whereas activation of Akt2 resulted a less prominent effect.
Nevertheless, our finding indicates that none of the AKT
isofoms were able to promote mesenchymal properties nor
enhance cell mobility in nonmalignant MCF10A cells, im-
plicating a potential tumor-repressing rather than tumor–
promoting role as indicated in previous reports [18-21].
Furthermore, to exclude the likelihood that our obser-
vation is due to the fact that MCF10A cells are immorta-
lized, this discovery was further substantiated by using
non-immortalized primary normal human mammary
epithelial cells (HMEC) isolated from three different

















Figure 1 Activated Akt signaling, regardless of isoform type, attenuat
MCF10A cells. A. Cells were infected with either control retrovirus Babe (V
total RNA was extracted from the respective cells and subjected to RT-qPC
mRNA levels of EMT-associated transcripts in Akt-infected cells compared t
resultant mixture was subject to Western immunoblotting using indicated
GAPDH expression was an indicative of nearly equal amounts of proteins inMCF10A cells, activation of Akt inhibited the expression
of mesenchymal-associated transcripts (Additional file 1:
Figure S1A) and reduced cell motility (Additional file 1:
Figure S1B) in HMECs from all three donors. These
effects were not associated with any specific Akt iso-
form, with the exception that expression of E-cad was
marginally repressed in HMEC-2 overexpressing Akt3 as
well as in HMEC-3 expressing all 3 isoforms (Additional
file 1: Figure S1A). Likewise, N-cad was largely inhibited
in HMEC-1 and -2, but activated in HMEC-3. We view
outliers as being probably ascribed to an induction of
another unreported adhesion molecule(s) that can trig-
ger an epithelial phenotype in lieu of E-cad activation or
N-cad repression. The variability might be due to the fact
that commercial primary breast epithelia are rather hetero-
geneous compared to MCF10A cells. Nevertheless, migra-
tion was prominently inhibited by activated Akt signaling
(Additional file 1: Figure S1B). Taken together, for the first
time by studying all three Akt isoforms, our data suggest
that overly activated Akt signaling can result in a noticeable
reduction of mesenchymal-associated transcripts as well as
a decrease in cell motility and these are observed in non-
malignant breast epithelial cells including not only immor-
talized MCF10A (Figures 1, 2 and 3) but also primary
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Figure 2 Activated Akt inhibits TGFβ-induced EMT in an
isoform-redundant manner. MCF10A cells were infected with
retroviruses to express empty vector (V), Akt1 (1), Akt2 (2) or Akt3 (3)
and then cultured in the absence or presence of TGFβ (2 ηg/ml, R &
D research) for 3 days followed by RT-qPCR to analyze EMT-
associated transcripts. Significant changes in the experimental
groups compared to vector control were marked with * or with #
(respectively denoting without or with TGFβ treatment) if p< 0.05.
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EMT in an isoform-independent manner
The Akt pathway axis has been reported to be
modulated by distinct isoforms [27,29]. Most functional
studies of Akt isoforms have been performed via gene-
specific xknockdown of specific Akt isoforms in
genetically modified mice. However, the latter is limited
by species conservation and potentially biased by the
fact that tumor-microenvironment in the mouse may
not always reflect the that in humans [34]. The discrep-
ancy of data evolved from the two system might be
ascribed to ectopic expression (current study) versus
knocking down endogenous Akt [27,29]. However,
knocking down specific Akt isoforms seems to be less
relevant than overexpression strategies since human car-
cinomas frequently display aberrant activation and amp-
lification rather than suppression of Akt signaling [17].
To decipher how different Akt isoforms influence
IGF-I-mediated EMT, MCF10A cells were retrovirally-
transduced to express IGF-IR that subsequently became
phosphorylated and activated (Figure 4A), which in turn
induces EMT [27] in response to ligand stimulation. How-
ever, we observed that ectopic expression of any isoform
of constitutively activated Myr-Akt largely attenuated the
EMT shift induced by IGF-IR stimulation since we
detected an increase of E-cad transcripts and a reduction
of FN1 and N-cad transcripts (Figure 4B). This observa-
tion was further supported by another experiment in
which knockdown Akt1 or Akt2 alone or in combination
by siRNA resulted in an opposite effect (E-cad, FN1, and
N-cad; compare Figure 4D to 4B). Noticeably, siRNA
knockdown of Akt exerted a less prominent effect on E-
cad expression. We speculate this outcome might be due
to compensatory effects provoked from aberrant pathways
that are influenced by a loss of Akt signaling. It is known
that expression of E-cad can be regulated by various sig-
naling pathways including interleukin-4 [35], Interleukin-
15 [36], miR-34a induced by hypoxia [37], ERK-MAPK
pathway triggered by C-Met signaling [38], and Wnt-
signaling cascade induced by leptin [39]. We hypothesize
that knocking down Akt by siRNA unexpectedly results in
perturbations in these pathways, and this subsequently
restores E-cad expression that is otherwise suppressed
(Figure 4D).
To confirm the suppressive effects of Akt signaling on
EMT, we also examined the ability of Akt signaling to re-
verse TGFβ-induced EMT. Treatment of MCF-10A cells
with 2 ηg/ml TGFβ induces EMT. However, overexpres-
sion of any Akt isoforms can decrease transcripts asso-
ciated with EMT (Figure 2) and can decrease cell motility
in transwell migration as well as wound-healing scratch
assays (Figure 3). Taken together, our data suggest an un-
reported finding that, in an isoform-independent manner,
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Figure 3 Akt signaling represses basal motility as well as TGFβ-induced migration in an isoform-independent manner. MCF10A cells
expressing vehicle control (V), Akt1 (1), Akt2 (2) or Akt3 (3) were either untreated or stimulated with TGFβ for 3 days. The motility of the resultant
cells was assessed either by migration assay at 12-hours (A and B) or wound healing assay 20-hours later (C).
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breast epithelial cells.
The molecular mechanisms responsible for down-
regulating TGFβ-induced EMT features by Akt were inves-
tigated further. We first examined epigenetic regulation
mediated by regional occupancy of various core nucleo-
some proteins. Post-translational modifications, including
methylation, acetylation, phosphorylation, or ubiquitination,
occurring at various residues laying in the N-termini of his-
tone proteins can result in either up- or down-regulation of
target gene expression [40]. “Histone code” works by either
changing the accessibility of chromatin or by recruiting
and/or occluding non-histone effector proteins to regulate
transcriptional activities [40]. By examining aberrant his-
tone occupancy on a panel of promoters of loci associated
with EMT, we discovered that occupancy of dimethylated
lysine 4 on histone H3 (H3K4me2), indicative of a tran-
scriptionally active chromatin, at the VIM promoter region
was lower in Akt-overexpressing MCF10A than the one in
vector control cells when the cells were treated with TGFβ
(Additional file 1: Figure S2). Interestingly enough, this ef-
fect closely paralleled the finding generated from both
transwell migration and wound-healing scratch assays
(Figure 3), indicating that reduced occupancy of H3K4me2
at VIM promoter might be correlated with Akt-mediated
inhibition of EMTand cell motility.Akt signaling reduces stem/progenitor subpopulations in
normal breast epithelia
EMT, as well as overexpression of HER2, activation of
PI3K, and loss of PTEN have all been associated with ac-
quisition of stem/progenitor cell properties [23,24,26,41-
43]. Since we demonstrated thatMyr-Akt was able to inhibit
EMT (Figures 1, 2, 3, 4), we decided to investigate if Akt
also inhibited the acquisition of the stem cell state. To do
this, we manipulated Akt expression in MCF-10A cells and
then measured the frequency of cells expressing a stem/
progenitor cell phenotype (CD44+/CD24-/low, ALDH+) as
well as having the ability to generate mammospheres in
non-adherent cultures. As shown in Figure 5A, MCF10A
cells expressing vehicle control (denoted as Babe) had ap-
proximately 14% of cells with a CD44+/CD24-/low pheno-
type, which is consistent with previous reports [44,45].
However, activation of respective Akt1, Akt2 or Akt3 uni-
formly decreased the frequency of this subpopulation to
0.5~1.7% of total cells (Figure 5A). Likewise, this inhibitory
effect mirrored the data generated by ALDEFLUOR assay
where the proportion of ALDH+ cells decreased from
~16% (in Babe control cells) to 3.6~4.6% (in cells overex-
pressing activated Akt) regardless of Akt isoform type
(Figure 5B). Our finding that activated Akt represses stem
cell fractions is consistent with other reports demonstrating
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Figure 4 Activated Akt inhibits IGF-1 induced EMT in an isoform-independent manner. A. Vector control or IGF-1R-expressing MCF10A
cells were either left untreated or treated with IGF-I (100 ng/mL) for 72 hours and then analyzed by Western immunoblot using indicated
antibodies. Authentication of IGF-1R expression was evidenced by an elevated phosphorylation of IGF-1R after IGF-I treatment. B. IGF-1R-
expressing MCF10A cells were infected with retrovirus expressing either vehicle control (V), or Akt1 (1), -2 (2), or -3 (3) and then subsequently
treated with IGF-I for an additional 3 days, followed by RT-qPCR analysis for assessing EMT-associated transcripts. Statistical significance was
denoted by * if the transcripts in Akt-expressing cells significantly (p< 0.05) differed from the ones in vector control cells (V). C. Knocking down
endogenous Akt by transfecting IGF-1R cells with siRNAs targeting either Akt1 or Akt2 or in combination were evidenced by a prominent loss of
Akt expression assessed by Western blots. D. In IGF-1R-exprssing MCF-10A cells pre-treated with IGF-1, knocking down Akt rescue altered EMT-
associated transcripts influenced by IGF-1R signaling (as compared to panel B).
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ing cells for the flow cytometric assays are described in
Additional file 1: Figures S3 and S5.
To confirm that Akt overexpression decreases the
stem/progenitor cell population using a functional assay,
cells overexpressing Akt as well as control cells were
seeded into the mammosphere assay and the frequency
of cells that can generate spheres was determined.
Results demonstrate that Myr-Akt expression was able
to reduce the frequency of mammosphere-initiating cells
in the parent populations compared to vector controls
(passage 3, Figure 5C). It is noteworthy to mention that
this inhibitory effect was not noticeable until later pas-
sages. For example, activated Akt expression enhanced
mammosphere formation during passage 1, whereas it
exerted marginal changes during passage 2. We interpret
this contradictory outcome as being due to Akt’s intrin-
sic property of facilitating anchorage-independent
growth [8], an effect that might interfere with the
current test analyzing mammosphere formation. How-
ever, this biasing effect gradually diminished over a
couple of passages and became a less interfering factorduring passage 3 (Figure 5C). Consequently, such biasing
factor might have underscored the extent of inhibiting
mammosphere formation that, otherwise, would have
been comparable to the CD44+/CD24-/low and ALDH+
phenotype data (Figure 5A and 5B). Taken together, the
effect of inhibiting stem/progenitors closely concurs with
our data describing the suppressive effects of Akt activa-
tion on EMT transcripts and cell motility (Figures 1, 2,
3, 4, 5).
Malignant state of breast epithelia dictates the EMT
inhibitory effects exerted from Akt signaling
Discrepancies among published findings regarding the
oncogenic roles Akt plays suggest a possibility that Akt
signaling might exert differential effects that are related to
the degree of malignancy of the cells and the cellular con-
text [27-30]. To investigate this further, the current study
was expanded to include a set of isogenic cell lines (MI,
MII and MIII) that were derived from MCF10A cells, but
later underwent a step-by-step oncogenic transformation
so that a series of lines with progressively increased tumori-
genicity was generated (from the lowest MI to the highest
ACD24
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Figure 5 Activated Akt signaling decreases breast stem/progenitor cell subpopulations. MCF10A cells were infected with retroviruses to
respectively express empty vector (Babe), Akt1, Akt2, or Akt3 and then subject to PE-CD24 and FITC-CD44 double-staining (A), ALDEFLUOR assay (B),
or serially passaged mammosphere formation assay from which mammospheres were counted under a microscope by independent investigators (C).
* Denotes that the number of mammospheres obtained from Akt-expressing cells differed significantly (p<0.05) from the vector controls.
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malignant MI and MII cells, but not MIII, displayed gener-
ally reduced expression of EMT-hallmarked transcripts
(Figure 6A) along with a declined motility (Figure 6B) in
response to activated Akt signaling. In general, aberrations
were more prominent in MI than in MII, implying an
inverse correlation between inhibitory effects and the ma-
lignant states of the cells. Along the same notion, the sup-
pressive effect became diminished in the highly malignant
cell line MIII (Figure 6A and 6B) and thereby indicating
that Akt-mediated inhibitory effects are likely to be blockedwhen cells have undergone advanced transformation. It is
possible that additional oncogenic pathways embedded in
MIII might have cross-talked with and thus liberated the
inhibitory effects provoked by Akt signaling.
The notion that advanced neoplastic features can combat
the inhibitory effect exerted from Akt activation was
substantiated by evaluating the influence of Akt on main-
tenance of stem/progenitor cell populations in the isogenic
cell line system. Despite the fact that the intrinsic stem/pro-
genitor subpopulations differ among MI, MII and MIII
(Figure 6C, vector control, Babe), overexpression of any of
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frequency of ALDH+ cells with mean inhibition rates
being> 40% in MI and> 50% in MII (Figure 6C, upper
panel), but rather negligible in MIII. As MIII harbors a
nearly undetectable ALDH+ subpopulation (nearly 2%),
the necessity of assessing the CD44+/CD24-/low phenotype
became apparent. Interestingly, we observed that the
fraction of CD44+/CD24-/low cells is proportional to the
malignant state (around 2%, 50% and 90% in MI, MII and
MIII cells, respectively) (Figure 6C, lower panel). Al-
though the inhibitory effect of Akt on MI was undetect-
able due to its extremely low basal level, MII was
influenced to a remarkable degree (from≥ 50% in Babe
control to ≤10% in Akt-expressing cells)(Figure 6C, lower
panel). In sharp contrast, this inhibitory effect was com-
pletely blocked in MIII cells (Figure 6C, lower panel).
Moreover, this rescuing effect is in close agreement with
data generated from the transwell migration assay
(Figure 6B). Together, they depict a novel paradigm that
Akt-mediated inhibition of EMT transcripts, cell motility,
and stem/progenitor cell expansion, is perhaps inversely
associated with the malignant status of breast epithelia.
Most importantly, this idea can be recapitulated in
advanced breast cancer cell lines (BrCa-MZ-01 and
SUM159) in which Myr-Akt expression rendered un-
detectable inhibitory effects on sustaining the ALDH+
subpopulation (Additional file 1: Figure S3).
Activated Akt signaling conveys resistance to cell death
induced by chemotherapeutic drugs
The findings presented above demonstrate that activated
Akt renders either inhibitory or marginal, but never enhan-
cing, effects on EMT transcripts, cell motility and in
maintenance of stem/progenitor cell populations. These
observations are paradoxical because they are opposite to
the general oncogenic effects normally associated with
Akt. To further delineate whether or not Akt activation
can exert other tumor-promoting effects, we assessed if
apoptotic death induced by two common chemotherapeu-
tic agents, paclitaxel and doxorubicin, can be halted.
As shown in Figure 7A and 7B, Akt activation dra-
matically augmented cell viability in response to drug
treatment. This protective effect spans a broad range
of doses (10-50 nM for paclitaxel and 600-900nM for
doxorubicin), supporting a notion that Akt activation
manifests its oncogenic effect minimally by preventing
cells from apoptotic death induced by cytotoxic agents.
Moreover, we showed that all 3 Akt isoforms exerted re-
dundant, rather than distinct or opposing effects in main-
taining cell viability.
Discussion
A growing body of evidence has demonstrated that activa-
tion of components within the PI3K cascade are associatedwith human carcinomas including colon, endometrium,
prostate, brain, ovarian, and breast cancers [15,48]. How-
ever, gain-of-function mutations leading to constitutive ac-
tivation of Akt are relatively uncommon (E17K is the most
frequent occurrence) [15,17], which contradicts a general
belief that Akt activation plays critical roles in driving neo-
plastic phenotypes. In breast cancer, the oncogenic roles
associated with Akt isoforms are still unclear and the dis-
crepancies may be due to factors associated with mouse
models vs. clinical studies, knockdown vs. overexpression,
and in vitro vs. in vivo [27-30,32,49]. Akt1 has been shown
to inhibit EMTas well as cell motility and these aberrations
can be rescued by Akt2, so that the net balance and ratio
between the two isoforms dictated the overall cell fate
[27,29]. However, this observation raised two unresolved
issues: (a) what upstream mediators, if any, would select
which isoforms to be activated; and (b) what downstream
targets can be uniquely transmitted in response to different
isoforms and exert distinct and perhaps opposing effects. In
the current report, we demonstrate that Akt isoforms ap-
pear to have redundant, rather than unique functions, when
promoting neoplastic features.
We have identified Akt1 as being the major isoform in
all breast epithelial cells examined in the current report
(Additional file 1: Figure S4). In other independent stud-
ies, however, activation of Akt1 was demonstrated to
suppress EMT [27], an event also important for stem
cell self-renewal [23,29]. Taken together, these findings
suggest that upregulated HER2 or knocked down PTEN
would have not only activated Akt1 signaling but also
repressed EMTand subsequently lowered stem/progenitor
subfraction. However, this rationale is contradictory to
data reported in previous publications [26,42]. Neverthe-
less, our present findings suggest an unreported paradigm
that all Akt isoforms are likely to behave similarly for
repressing cell migration, EMT, and stem/progenitor func-
tion, rather than exerting antagonistic effects by interact-
ing among various isoforms. Two possibilities may explain
the discrepancies between our data and others. Not only
does the malignant state and cell context dictate Akt’s in-
hibitory effects (Figure 6), but the published findings are
mainly generated from Akt knockdown studies that might
induce unexpected feedback signaling. Notably, loss of
Akt may not be physiologically relevant since most human
carcinomas are associated with activation, rather than an
inhibition, of Akt signaling. To date, Akt ablation has
not been reported for any of the known human malig-
nancies. Regarding isoform specificity, our current data
cannot completely exclude the possibility that other un-
disclosed downstream targets or events might respond
to Akt activation in an isoform-specific manner. However,
this issue is beyond the scope of our current study.
The inhibition of cell migration and EMT by Myr-Akt
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Figure 6 The inhibitory effects of Akt signaling on EMT, cell motility and stem/progenitor cell subfraction can be attenuated in cells
that become progressively malignant. A. MI, MII and MIII cells were infected with retroviruses expressing vector control (Babe), Akt1 (1), Akt2
(2), or Akt3 (3), followed by RT-qPCR analysis for assessing expression levels of EMT-associated transcripts. Heatmap represents relative mRNA
levels of various transcripts in Akt-expressing cells compared to the ones in control cells set as 1. B. Infected MI, MII, or MIII cells were tested for
migration assay 12 hours after seeding on the top chamber of transwell plate and * denotes a significant change (p< 0.05) as compared to the
control cells (Babe). C. Infected MI, MII or MIII cells were subjected to ALDEFLUOR staining (upper) or PE-CD24 plus FITC-CD44 double-staining
(lower), followed by FACS analysis to quantify the frequency of ALDH+ and CD44+/high/CD24-/low subpopulations. * denotes significant (p < 0.05)
difference between the Akt-expressing cells and the counterpart control.
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is supported by a clinical study from a large cohort of
breast tumors (N= 590) in which the women who car-
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expression of HER2 or from knockdown of PTEN by
ShRNA [26,42]. We reason the discrepancy is likely due
to the fact that dysregulated HER2 and PTEN can
trigger far broader downstream targets beside Akt. For
instance, other than acting as a phosphatase to attenuate
activated Akt, PTEN can regulate cell cycle progression,
stem cell self-renewal, chromosome stability, and senes-
cence [50]. Likewise, additional signaling cascades down-
stream from PI3K include mitogen-activated protein
kinase (MAPK), extracellular signal-related kinase (ERK),
and Wnt/β-catenin, which may synergistically promote
stem-progenitor self-renewal and override the inhibitory
effect solely incurred from Akt. It is worthy to mention
that PI3K signaling can lead to not only Akt-dependent
but also Akt–independent activation [51] and the latter
might be partly responsible for combating the inhibitory
effect from the former.
The present report demonstrates that in spite of exert-
ing tumor-suppressing effects, Akt can render an oppos-
ing oncogenic event by resisting cell death induced by
the action of cytotoxic drugs. It thereby suggests that not
only ectopically expressed Myr-Akt retained authentic
functionality, but also that Akt signaling regulates pleotro-
pic downstream substrates, each of which exerts distinct
outcomes. For instance, Forkhead transcription factors
(FOXO1), BAD, caspase 9, and NF-κB seem to be respon-
sible for protecting cells from apoptosis, whereas mTOR
and Wnt/β-catenin signaling might be involved in regulat-
ing stem/progenitor cells [23]. In support of this notion, we
have observed that, besides repressed EMT and stem cell
self-renewal, overexpresssion of Myr-Akt protected cells
from apoptotic death induced by Paclitaxel as well as by
Doxorubicin (Figure 7). Coincidently, our finding about re-
sistance to apoptosis induced by Doxorubicin intervention
can be supported by independent data generated from
in vitro knockdown of PTEN in cell culture system [52].Conclusions
We present a novel paradigm that Akt activation can
have dichotomous effects on neoplastic progression.
Akt’s intrinsic property of tumor-suppressive effects is
demonstrated by repression of EMT, cell motility, and
stem/progenitor cell expansion, and that the effects are
notably distinct from its tumor-promoting functions that
enhance cell survival. While the former would confine
the target cells (mainly at non- or low-malignant states)
to the local sites, the latter partly contributes to its
oncogenic effect. Restrained cells then await additional
tumorigenic signals presumably provoked from tumor
microenvironmental factors or from additional carcino-
genic insults that would alleviate the tumor-suppressive
effect of Akt prior to metastatic spread. Meanwhile,epithelial cells would be maintained in a viable state dur-
ing the course of therapeutic drug treatments.
Materials and methods
Cell culture, retroviral infections and siRNA delivery
Normal human mammary epithelial cells (HMEC)
derived from three different subjects were purchased
from and authenticated by Lonza as well as ScienceCell
Research Laboratories and cultured in mammary epithe-
lial growth medium (MEGM) (Lonza). MCF10A, the
spontaneously immortalized human normal epithelial
cell line, was acquired from and authenticated by Ameri-
can Type Culture Collection (Manassas, VA). MCF10A1
(MI), MCF10AT1k.cl2 (MII) and MCF10CA1h (MIII)
cells [47] were obtained from Barbara Ann Karmanos
Cancer Institute (Detroit, MI) and grown in DMEM/F12
medium (Mediatech) supplemented with 5% horse serum,
EGF (20 ηg/ml), insulin (10 μg/ml), hydrocortisone (500
ηg/ml), and cholera toxin (100 ηg/ml). The BrCa-MZ-01
and SUM159 breast cancer cells were generous gifts from
Dr. Max S. Wicha (University of Michigan, Ann Arbor,
Michigan) and are commercially available (Asterand, De-
troit, MI). BrCa-MZ-01 cells were maintained in RPMI1640
supplemented with 10% Fetal Bovine Serum (FBS) whereas
SUM159 was propagated in F12 medium (Mediatech) with
5% FBS, insulin (5 μg/ml), and hydrocortisone (1 μg/ml).
Antibiotic-antimycotic (100 U/ml penicillin, 100 μg/ml
streptomycin and 0.25 μg/ml amphoterincin) was
routinely included in medium to prevent microbial
contamination.
pBabe-Puro, pBabe-Puro-Myr-Flag-Akt1 [8], pBabe-
Puro-Myr-HA-Akt2, pBabe-Puro-Myr-HA-Akt3, pBabe-
Bleo, and pBabe-Bleo-IGF-1R, were purchased from
Addgene Inc. To obtain infectious retrovirions prior to
transducing Myr-Akt into target cells, retroviral vectors
were first introduced into packaging cells known as
PhoenixTM Ampho (Orbigen, Inc.) by a calcium phosphate
transfection method. 24 hours later, the medium was
replenished and the resultant supernatant was collected
twice at 12-hour intervals and each harvest was immedi-
ately overlaid on the target cells. Afterwards, the infected
cells were selected for with either 2.5 μg/ml puro-
mycin (for pBabe-Puro vector) or with 500 μg/ml zeocin
(for pBabe-Bleo backbone plasmids) for 7 days and the
drug-resistant cells were then collected on the 14th day
after infection.
FBS, horse serum, B27 serum-free supplement, basic
fibroblast growth factor (bFGF) and zeocin were obtained
from Invitrogen; EGF, cholera toxin, hydrocortisone, insu-
lin, puromycin, paclitaxel and poly-HEMA were purchased
from Sigma; and Doxorubicin was from Calbiochem.
For knocking down endogenous Akt expression using
RNA interference (siRNA), IGF-1R-expressing MCF10A
cells (transduced by pBabe-Bleo-IGF-1R retrovirus) were
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con ONTARGETplus siRNA SMARTpool reagents
against individual or combinations of the Akt1 and Akt2
(Thermo Scientific Cat # L-003000-00 and L-003001-00,
respectively) following the protocols recommended by
the manufacturer (Thermo Scientific). To generate a
negative control, cells were similarly transfected with the
ON-TARGETplus Non-Targeting siRNA Pool (Thermo
Scientific Cat # D-001810-10).Western blot analysis
Cells were lysed in NP-40 lysis reagent (1% NP-40, 50 mM
Tris, pH 7.6, and 150 mM NaCl) or in RIPA lysis buffer
(Cell signaling) supplemented with protease inhibitor cock-
tail tablets (Roche). 30-50 μg of proteins were resolved by
8-10% SDS-PAGE and immunoblotted using standard
techniques. Antibodies recognizing phosphorylated Akt
(Ser 473), N-cadherin, Akt (pan), Akt1, Akt2, Akt3,
GAPDH, phosphorylated and pan IGF-1R were obtained
from Cell Signaling Technology whereas the antibodies re-
spectively recognizing E-cadherin, fibronectin, and vimen-
tin were purchased from BD Biosciences.Reverse transcription followed by quantitative real-time
PCR analysis (RT-qPCR)
Total RNA was extracted with Trizol (Invitrogen) and
1.0 μg of which served as the templates for synthesizing
complementary DNA (cDNA) by using SuperScript III
reverse transcriptase (Invitrogen). The resultant cDNA
together with the RT2 SYBR Green qPCR Master Mixes
(SABiosciences) were used for real-time PCR analysis on a
7500 fast real-time PCR machine (Applied Biosystems).
Quantification of mRNA expression was normalized to the
internal transcript of GAPDH. The primers used for
GAPDH were 5’-CCCCTTCATTGACCTCAACTACAT-3’
(forward) and 5’-CACTCCTGGAAGA TGGTGA-3’
(reverse). Other primers utilized for amplification of EMT-
associated transcripts were described previously [23].Transwell migration assay
Cells obtained from sub-confluent culture were disso-
ciated by trypsinization and resuspended in limiting cul-
ture medium containing a reduced concentration of
serum or devoid of bovine pituitary extract (BPE). 2-5×104
of the resultant cells were loaded into the top chambers of
24-well transwell plates (8 μm pore size; BD Biosciences)
whereas the bottom chambers were filled with only regular
culture medium without any cells. About 12-24 hours later,
the non-motile cells at the top of the filter were swapped
off with cotton swabs while the motile cells at the bottom
of the filter were fixed with 70% ethanol and stained with
0.1% crystal violet. The number of migrated cells wasquantified by the counting of 10 fields under 20X magnifi-
cation of a microscope to generate an average value.
Wound healing assay
Approximately 5 × 104 cells were plated into each well of
6-well plates and treated with either vehicle control or
with 2 ηg/ml TGFβ (R & D Systems) for 3 days. On the
day of the experiment, the monolayer of confluent cells
was lightly scratched with a pipette tip and photo-
graphed immediately and 20 hours later. The ability of
healing the scratched wound was accessed using ImageJ
software by calculating % of decreased scratch area at 20
hours in relation to the one at 0 hour. At least 10
scratch areas were scored to generate an average value.
Flow cytometry
Cells were trypsinized, washed once with ice-cold stain/
wash buffer (HBSS + 2% FBS), and then resuspended at a
concentration of 1 × 107/ml in which specific antibody
was added. Cells were incubated for an additional 20-30
minutes on ice, washed twice with the same buffer and then
subject to flow cytometry analysis using BD FACSAria Flow
Cytometer (BD Biosciences). The antibodies recognizing
PE-CD24 (clone ML5), FITC-CD44 (clone G44-26), and
their isotype controls were obtained from BD Biosciences.
During the flow cytometric analysis, the vast majority of in-
tact cells were gated based on forward and side scattering
plots. Cells stained with PE- normal IgG and FITC- normal
IgG were used to set up respective gates for PE-CD24 and
FITC-CD44 single staining. The resultant baselines subse-
quently generated the combinatorial gate for quantifying
CD24 plus CD44 doubly stained cells (Additional file 1:
Figure S5). The cells displaying CD44+/CD24-/low were
regarded as the subpopulation enriched with stem/progeni-
tor cells (Additional file 1: Figure S5F).
ALDEFLUOR assay
The ALDEFLUOR kit (StemCell Technologies) was
employed to quantify the subpopulation of cells with a
high ALDH enzymatic activity. Briefly, cells were trypsi-
nized, resuspended at a concentration of 1 × 106/ml in
ALDEFLUOR assay buffer containing ALDH substrate
(BAAA), and incubated for an additional 30-60 minutes
at 37°C. To generate a cell faction representing a base-
line negative control, a small aliquot of the respective
sample was incubated with DEAB (a specific ALDH in-
hibitor) immediately after the addition of BAAA. After
incubation, stained cells were washed with ice-cold wash
buffer (1 ×HBSS+ 2% FBS) twice and then subject to
flow cytometry analysis as previously described [53].
Cells harboring ALDH activity higher than the baseline
level (upper panels of Additional file 1: Figures S3A and
S3B) were scored as an ALDH+ subfraction that is
enriched for stem/progenitor cells.
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Growth of mammospheres was carried out as previously
described [54]. Briefly, single cell suspensions at a density
of 1-5×103/ml were plated in serum-free mammary epithe-
lial basal medium (MEBM) (Lonza) supplemented with
B27, EGF (30 ηg/ml), bFGF (20 ηg/ml), insulin (5 μg/ml),
hydrocortisone (0.5 μg/ml), heparin (4 μg/ml), gentamycin
(4 μg/ml) and antibiotic-antimycotic in poly-HEMA-coated
culture dishes. 10-14 days later, the number of mammo-
spheres with sizes of ≥70 μm were either counted or further
dissociated into another single-cell suspensions and grown
for a subsequent passage assay.
Survival assay
Approximately 8,000 cells at their exponential growth stage
were seeded in each well of 96-well plates in triplicates. On
the next day, cells were treated with various concentrations
of doxorubicin or paclitaxel for 2 or 5 days, and then viable
cells were quantified using MTT.
Statistical analysis
The Student’s t test was carried out to assess if the dif-
ferences between experimental samples to the control
were significant (indicated by p < 0.05).
Additional file
Additional file 1: Dichotomy Effects of Akt Signal on Breast
Neoplasm.
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